Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
0.4047
+0.0037 (0.92%)
At close: Aug 24, 2026, 4:00 PM EDT
0.4000
-0.0047 (-1.16%)
After-hours: Aug 24, 2026, 5:19 PM EDT
Soligenix Employees
As of December 31, 2025, Soligenix had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees decreased by 2 or -12.50% compared to the previous year.
Employees
14
Change (1Y)
-2
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$731,390
Market Cap
8.81M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | -2 | -12.50% | 13 | 1 |
| Dec 31, 2024 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2023 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2022 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2021 | 15 | -3 | -16.67% | 13 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Imunon | 20 |
| FibroBiologics | 15 |
| Azitra | 13 |
| CNS Pharmaceuticals | 8 |
| Aprea Therapeutics | 8 |
| AEON Biopharma | 8 |
| Traws Pharma | 7 |
| Immuron | 7 |
SNGX News
- 17 days ago - Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results - PRNewsWire
- 17 days ago - Soligenix Quarterly report: Q2 2026 - Filings
- 21 days ago - Soligenix Proxy statement: Proxy filing - Filings
- 21 days ago - Soligenix Proxy statement: Proxy filing - Filings
- 4 weeks ago - Soligenix Proxy statement: Proxy filing - Filings
- 4 weeks ago - Soligenix Proxy statement: Proxy filing - Filings
- 2 months ago - Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine - TheFly
- 2 months ago - Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine - PRNewsWire